TrialNCT07416552
A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
- Status
- RECRUITING
- Phase
- PHASE1
- Last update posted
- 09/04/2026
- Start
- 09/08/2026
- Sponsor
- Hoffmann-La Roche
- Specialties
- oncology
Conditions: Metastatic Colorectal Cancer
Brief summary
This study will evaluate the dosimetry, safety, efficacy, pharmacokinetics (PK), pharmacodynamics and immunogenicity of CEA-PRIT 2.0 in participants with metastatic microsatellite-stable (MSS) mCRC who are intolerant to or have progressed after having received available standard-of-care (SOC) therapies.
Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.